<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Anthera Pharmaceuticals, Inc.

    Anthera Pharmaceuticals, Inc.

    Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focu...

    Anthera Pharmaceuticals, Inc., a development st...

    Amount Raised:    $65,500,000
    Fundraising Status:    VT
    Filing Type:    PU
    Arena Pharmaceuticals, Inc.

    Arena Pharmaceuticals, Inc.

    Arena Pharmaceuticals is driven to deliver novel, transformational medicines with ...

    Arena Pharmaceuticals is driven to deliver nove...

    Filing Type:    PU
    Halo Cures, Inc.

    Halo Cures, Inc.

    Halo gives scientists and academics opportunities to connect with industry partner...

    Halo gives scientists and academics opportuniti...

    Filing Type:    CF
    Cara Therapeutics, Inc.

    Cara Therapeutics, Inc.

    Cara Therapeutics is a clinical-stage biopharmaceutical company focused on develop...

    Cara Therapeutics is a clinical-stage biopharma...

    Filing Type:    PU
    Reata Pharmaceuticals, Inc.

    Reata Pharmaceuticals, Inc.

    Reata is a clinical-stage biopharmaceutical company that develops novel therapeuti...

    Reata is a clinical-stage biopharmaceutical com...

    Filing Type:    PU
    Neurocarrus Inc

    Neurocarrus Inc

    Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet ne...

    Neurocarrus is developing a breakthrough therap...

    Amount Raised:    $344,168.00
    Fundraising Status:    EC
    Filing Type:    CF
    Midatech Pharma PLC

    Midatech Pharma PLC

    Midatech is an international specialty pharmaceutical company focused on the devel...

    Midatech is an international specialty pharmace...

    Filing Type:    PU
    Rexahn Pharmaceuticals, Inc.

    Rexahn Pharmaceuticals, Inc.

    Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to ...

    Rexahn Pharmaceuticals is a clinical stage biop...

    Filing Type:    PU
    bluebird bio, Inc.

    bluebird bio, Inc.

    bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., h...

    bluebird bio is pioneering gene therapy with pu...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.